HealthcareServices

Prostate Cancer Nuclear Medicine Diagnostics Market Size and Growth Forecast for Businesses 2025–2029

November 26, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Prostate Cancer Nuclear Medicine Diagnostics Market?

The prostate cancer nuclear medicine diagnostics market has demonstrated rapid expansion in recent years. Its size is anticipated to rise from $0.86 billion in 2024 to $0.99 billion in 2025, achieving a compound annual growth rate (CAGR) of 14.8%. This growth observed during the past period can be ascribed to several factors, including the increasing demand for PET scans, growing urbanization, a rise in disposable income, the escalating need for accurate cancer diagnosis, and an intensified emphasis on early detection.

The prostate cancer nuclear medicine diagnostics market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $1.65 billion by 2029, growing at a compound annual growth rate (CAGR) of 13.8%. The impetus for this growth during the forecast period stems from the increasing incidence of prostate cancer, a greater demand for positron emission tomography, rising awareness concerning environmental sustainability, the escalating frequency of various cancers, and advancements in digital transformation. Significant trends anticipated in this period include ongoing product innovation, continuous technological advancements, enhancements in nuclear medicine imaging, the development of more effective radiopharmaceuticals and imaging techniques, and the introduction of novel radiopharmaceuticals.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15906&type=smp

What Are The Top Growth Drivers Impacting The Prostate Cancer Nuclear Medicine Diagnostics Market Outlook?

The increasing occurrence of prostate cancer is anticipated to drive the expansion of the prostate cancer nuclear medicine diagnostics market moving forward. Prostate cancer is a malignancy affecting the prostate, a small, walnut-sized gland in males responsible for producing seminal fluid that supports and transports sperm. The growing incidence of prostate cancer stems from an aging demographic, changes in lifestyle, and genetic predispositions. These nuclear medicine diagnostics offer crucial data, empowering medical professionals to provide more accurate, effective, and tailored treatment to individuals with prostate cancer. As an example, the World Health Organization, a Switzerland-based body focused on global public health, reported in February 2024 that by 2050, more than 35 million new cancer cases are expected, marking a 77% rise from the approximately 20 million cases in 2022. Consequently, the increasing prevalence of prostate cancer is a key factor propelling the prostate cancer nuclear medicine diagnostics market.

What Are The Key Segments In The Prostate Cancer Nuclear Medicine Diagnostics Market?

The prostate cancer nuclear medicine diagnosticsmarket covered in this report is segmented –

1) By Type: Single Photon Emission Computed Tomography (SPECT); Photon Emission Computed Tomography (PET)

2) By Test Type: Preliminary Tests; Confirmatory Tests

3) By End User: Hospitals; Clinics; Other End Users

Subsegments:

1) By Single Photon Emission Computed Tomography (SPECT): Gamma Camera SPECT; Hybrid SPECT Or CT Imaging

2) By Positron Emission Tomography (PET): PET Or CT Imaging; PET Or MRI Imaging

What Trends Are Expected To Drive The Prostate Cancer Nuclear Medicine Diagnostics Market?

Key companies engaged in the prostate cancer nuclear medicine diagnostics market are developing innovative diagnostic imaging techniques and obtaining US Food and Drug Administration (FDA) approval. FDA clearance for diagnostics ensures that healthcare providers and patients have access to safe and effective tests for diagnosing and managing various medical conditions. For instance, in March 2022, Novartis, a Switzerland-based pharmaceutical corporation, launched Pluvicto(lutetium Lu 177 vipivotide tetraxetan) for treating adult patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) of a specific type known as prostate-specific membrane antigen–positive (PSMA-positive) that has spread to other areas of the body. Pluvicto integrates a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle), offering a precision cancer treatment that specifically targets prostate cancer cells expressing the prostate-specific membrane antigen (PSMA).

Which Industry Leaders Are Driving Innovation Across The Prostate Cancer Nuclear Medicine Diagnostics Market?

Major companies operating in the prostate cancer nuclear medicine diagnostics market are Cardinal Health, General Electric, Bayer AG, Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, CURIUM PHARMA, Telix Pharmaceuticals Ltd., Eckert & Ziegler AG, Point Biopharma Global Inc., Point Biopharma, Alliance Medical Ltd., SHINE Medical Technologies LLC, PETNET Solution, NorthStar Medical Radioisotopes LLC, Global Medical Solutions LLC, Isotope Technologies Garching (ITG), Jubilant Pharma Limited, Blue Earth Diagnostics Inc., Institute of Isotopes Co. Ltd., Radiopharm Theranostics, Bracco Diagnostic Inc., NCM-USA LLC, ABX Advanced Biochemical Compounds GmbH

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Prostate Cancer Nuclear Medicine Diagnostics Market?

North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2024. The regions covered in the prostate cancer nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Prostate Cancer Nuclear Medicine Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=15906&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Nuclear Medicine Diagnostics Market 2025, By The Business Research Company

Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Cervical Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cervical-cancer-diagnostics-global-market-report

Lung Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795